SpecChem, LLC – Trademark Portfolio
Entity Type: 16
SpecChem, LLC owns a portfolio of 28 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), including well-known marks such as E-CURE, REPCON, POLYFIX, POR-ROK, and SPECPOXY. Of these, 19 are registered. The portfolio spans 5 Nice Classification classes, led by Class 19 (Building Materials) and Class 1 (Chemicals). Headquartered in Kansas City, MO.
1511 Baltimore Ave., Suite 600
Kansas City, MO 64108
Showing of trademarks Trademarks
Trademark Classifications
SpecChem, LLC's trademark portfolio spans 5 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Building materials (non-metallic); non-metallic rigid pipes for building
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Paints, varnishes, lacquers; preservatives against rust and against deterioration of wood
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Frequently Asked Questions
How many trademarks does SpecChem, LLC have?
SpecChem, LLC has 28 U.S. trademarks filed with the USPTO. Of these, 19 registered, 9 abandoned.
What trademark classes does SpecChem, LLC file in?
SpecChem, LLC files trademarks across 5 Nice Classification classes. The most active classes are Class 19 (Building Materials), Class 1 (Chemicals), Class 2 (Paints), Class 17 (Rubber Goods), Class 3 (Cosmetics & Cleaning). Class 19 covers building materials (non-metallic); non-metallic rigid pipes for building.
What are SpecChem, LLC's most well-known trademarks?
SpecChem, LLC's registered trademark portfolio includes well-known marks such as E-CURE, REPCON, POLYFIX, POR-ROK, and SPECPOXY. These are among 19 currently registered trademarks in the portfolio.
What is SpecChem, LLC's trademark registration success rate?
SpecChem, LLC has a 68% trademark registration rate, with 19 out of 28 resolved applications resulting in successful registration. Currently, 0 applications are pending review.